Cosmo N.V. (SWX: COPN)
Health Care · Pharmaceuticals · IE
CHF58.30
+1.04% today · 0.0% 1Y
Cosmo N.V. (SWX: COPN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.25B and employs 325 people.
Over the last twelve months the share price has gained 0.0%, trading between 55.20 and 129.40.
Tweenvest scores Cosmo N.V. across four factors: quality 66/100, value 60/100, growth 25/100, dividend 61/100. Its strongest factor is quality.
COPN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.25B
- Revenue (TTM)
- $117.32M
- P/E
- —
- EPS
- -0.38
- Dividend yield
- 3.41%
- Beta (5Y)
- 1.48
- 52-week high
- CHF129.40
- 52-week low
- CHF55.20
- Avg volume (3M)
- —
- Shares outstanding
- 17.19M
- Employees
- 325
- Next earnings
- —
About Cosmo N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
- ISIN
- NL0011832936
- Founded
- 1997
- Listed since
- Mar 12, 2007
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,243.44 | -0.28% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.68 | -0.86% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.46 | -0.13% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.30 | +0.24% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.24 | +0.94% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.92 | -0.18% |
Figures last refreshed Aug 18, 2026.